A central concept behind IDO1 inhibitor development for cancer centered on the TRP-dependent cross-talk in the TME between IDO1-expressing tumor, myeloid cells, and T cells whose proliferation would be suppressed by local TRP restriction. Here, IDO1 is linked to neoplasm.